Sivia Capital Partners LLC Grows Stake in Pfizer Inc. (NYSE:PFE)

Sivia Capital Partners LLC boosted its holdings in Pfizer Inc. (NYSE:PFE) by 21.9% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 12,375 shares of the biopharmaceutical company’s stock after purchasing an additional 2,220 shares during the quarter. Sivia Capital Partners LLC’s holdings in Pfizer were worth $346,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the stock. Olistico Wealth LLC purchased a new position in shares of Pfizer in the 2nd quarter valued at $25,000. MFA Wealth Advisors LLC purchased a new position in shares of Pfizer during the second quarter worth about $29,000. Creekmur Asset Management LLC acquired a new stake in shares of Pfizer during the fourth quarter worth about $32,000. Trivant Custom Portfolio Group LLC lifted its holdings in shares of Pfizer by 100.0% in the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 600 shares during the last quarter. Finally, Financial Connections Group Inc. acquired a new stake in shares of Pfizer in the 2nd quarter valued at about $34,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on PFE. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Monday, August 19th. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and raised their price objective for the stock from $28.00 to $34.00 in a research report on Wednesday, August 7th. Wells Fargo & Company lifted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Finally, UBS Group increased their target price on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. Eight research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Pfizer presently has an average rating of “Moderate Buy” and an average target price of $34.54.

Pfizer Stock Performance

Shares of PFE opened at $28.56 on Friday. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $34.64. The stock has a market cap of $161.84 billion, a P/E ratio of -476.00, a PEG ratio of 1.02 and a beta of 0.68. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. The company has a 50-day moving average of $29.06 and a two-hundred day moving average of $28.05.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.14. The company had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. Pfizer’s revenue was up 2.1% compared to the same quarter last year. During the same quarter last year, the business posted $0.67 earnings per share. As a group, research analysts predict that Pfizer Inc. will post 2.66 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th were issued a dividend of $0.42 per share. The ex-dividend date of this dividend was Friday, July 26th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.88%. Pfizer’s dividend payout ratio (DPR) is presently -2,800.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.